Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

Treatment of multiple myeloma (MM) has advanced dramatically in the past two decades. However, under the conditions of the COVID-19 pandemic, treatment strategies have been modified accordingly. Numerous novel agents, updated trials, and major advances in myeloma have been reported in the American S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianhua Du, Junling Zhuang
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2021
Materias:	Multiple myeloma Autologous stem cell transplantation Monoclonal antibody Chimeric antigen receptor-T Novel agents Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0cde6c5d687d4dfb96f5f89bf86d6846
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0cde6c5d687d4dfb96f5f89bf86d6846
record_format	dspace
spelling	oai:doaj.org-article:0cde6c5d687d4dfb96f5f89bf86d68462021-12-02T18:04:06ZMajor advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 20202095-882X10.1016/j.cdtm.2021.08.003https://doaj.org/article/0cde6c5d687d4dfb96f5f89bf86d68462021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X21000529https://doaj.org/toc/2095-882XTreatment of multiple myeloma (MM) has advanced dramatically in the past two decades. However, under the conditions of the COVID-19 pandemic, treatment strategies have been modified accordingly. Numerous novel agents, updated trials, and major advances in myeloma have been reported in the American Society of Hematology 2020 annual meeting, either for transplant-eligible or ineligible patients. Hot topics such as the significance of autologous stem cell transplantation (ASCT), development of novel agents, and chimeric antigen receptor-T (CAR-T) cells have been widely discussed. The triplet regimen bortezomib, lenalidomide, and dexamethasone (VRd) is recommended as the standard first-line treatment, and the addition of a fourth drug improves efficacy and survival. The value of ASCT remains undoubtful, even in the era of quadruplet induction. Dual-drug maintenance, including proteasome inhibitors and immunomodulatory drugs, overcomes unfavorable outcomes in high-risk patients. For relapsed/refractory myeloma (RRMM) patients, novel agents such as selinexor and venetoclax are superior. CAR-T cells and other cell-surface-targeted therapies also appear promising.Jianhua DuJunling ZhuangKeAi Communications Co., Ltd.articleMultiple myelomaAutologous stem cell transplantationMonoclonal antibodyChimeric antigen receptor-TNovel agentsMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 7, Iss 4, Pp 220-226 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multiple myeloma Autologous stem cell transplantation Monoclonal antibody Chimeric antigen receptor-T Novel agents Medicine (General) R5-920
spellingShingle	Multiple myeloma Autologous stem cell transplantation Monoclonal antibody Chimeric antigen receptor-T Novel agents Medicine (General) R5-920 Jianhua Du Junling Zhuang Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
description	Treatment of multiple myeloma (MM) has advanced dramatically in the past two decades. However, under the conditions of the COVID-19 pandemic, treatment strategies have been modified accordingly. Numerous novel agents, updated trials, and major advances in myeloma have been reported in the American Society of Hematology 2020 annual meeting, either for transplant-eligible or ineligible patients. Hot topics such as the significance of autologous stem cell transplantation (ASCT), development of novel agents, and chimeric antigen receptor-T (CAR-T) cells have been widely discussed. The triplet regimen bortezomib, lenalidomide, and dexamethasone (VRd) is recommended as the standard first-line treatment, and the addition of a fourth drug improves efficacy and survival. The value of ASCT remains undoubtful, even in the era of quadruplet induction. Dual-drug maintenance, including proteasome inhibitors and immunomodulatory drugs, overcomes unfavorable outcomes in high-risk patients. For relapsed/refractory myeloma (RRMM) patients, novel agents such as selinexor and venetoclax are superior. CAR-T cells and other cell-surface-targeted therapies also appear promising.
format	article
author	Jianhua Du Junling Zhuang
author_facet	Jianhua Du Junling Zhuang
author_sort	Jianhua Du
title	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
title_short	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
title_full	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
title_fullStr	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
title_full_unstemmed	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
title_sort	major advances in the treatment of multiple myeloma in american society of hematology annual meeting 2020
publisher	KeAi Communications Co., Ltd.
publishDate	2021
url	https://doaj.org/article/0cde6c5d687d4dfb96f5f89bf86d6846
work_keys_str_mv	AT jianhuadu majoradvancesinthetreatmentofmultiplemyelomainamericansocietyofhematologyannualmeeting2020 AT junlingzhuang majoradvancesinthetreatmentofmultiplemyelomainamericansocietyofhematologyannualmeeting2020
_version_	1718378671817883648

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

Ejemplares similares